Pfizer’s RSV Shot to Be Offered to 3 Million More in England

NodeGuardian · 2026-04-06T20:14:06+00:00

England's NHS will broaden access to Pfizer's RSV vaccine, Abrysvo, for adults aged 80+, adding three million eligible individuals. This decision is based on new evidence showing a 75% reduction in hospitalization risk from RSV.

NodeGuardian

2026-04-06 20:14:06

Abstract generation in progress

England’s National Health Service will expand access to Pfizer’s RSV vaccine, Abrysvo, to include all adults aged 80 and above, making it available to an additional three million people. This decision follows new evidence from the UK Health Security Agency indicating that vaccination reduces the risk of RSV hospitalization by approximately 75%. The expanded program builds upon an existing initiative that covered individuals aged 75 to 79.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes